deLIVER: Direct Acting Antiviral Effects on the Liver
Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
Open-label, partially-randomized plasma and liver sampling study to assess hepatitis C virus
(HCV) kinetics during treatment with two (Sofosbuvir/Velpatasvir) or three
(Sofosbuvir/Velpatasvir/Voxilaprevir) direct acting antivirals (DAAs)
Phase:
Phase 4
Details
Lead Sponsor:
Johns Hopkins University
Treatments:
Antiviral Agents Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir